首页> 美国卫生研究院文献>Sarcoma >Progress in the Molecular Biology of Ewing Tumors
【2h】

Progress in the Molecular Biology of Ewing Tumors

机译:尤因肿瘤的分子生物学研究进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose/results/discussion. Rearrangement of the EWS gene with an ETS oncogene by chromosomal translocation is a hallmark of the Ewing family of tumors (EFT). Detectability, incidence, tumor specificity and variability of this aberration have been matters of intense investigation in recent years. A number of related alterations have also been found in other malignancies. The common consequence of these gene rearrangements is the generation of an aberrant transcription factor. In EFT, the ETS partner is responsible for target recognition. However, synergistic and possibly tissue-restricted transcription factors interacting with either the EWS or the ETS portion may influence target selection. Minimal domains of both fusion partners were defined that have proved necessary for the in vitro transformation of murine fibroblasts. These functional studies suggest a role for aberrant transcriptional regulation of transforming target genes by the chimeric transcription factors. Also, fusion of the two unrelated protein domains may affect overall protein conformation and consequently DNA binding specificity. Recent evidence suggests that EWS, when fused to a transcription factor, interacts with different partners than germ-line EWS. Variability in EWS–ETS gene fusions has recently been demonstrated to correlate with clinical outcome. This finding may reflect functional differences of the individual chimeric transcription factors. Alternatively, type and availability of specific recombinases at different time-points of stem cell development or in different stem cell lineages may determine fusion type. Studies on EFT cell lines using EWS–ETS antagonists do suggest a rate-limiting essential role for the gene rearrangement in the self-renewal capacity of EFT cells. The presence of additional aberrations varying in number and type that may account for immortalization and full transformation is postulated. Knowledge about such secondary alterations may provide valuable prognostic markers that could be used for treatment stratification.
机译:目的/结果/讨论。 EWS基因与ETS癌基因通过染色体易位重排是Ewing肿瘤家族(EFT)的标志。近年来,这种像差的可检测性,发生率,肿瘤特异性和变异性已成为深入研究的问题。在其他恶性肿瘤中也发现了许多相关的改变。这些基因重排的共同结果是异常转录因子的产生。在EFT中,ETS合作伙伴负责目标识别。但是,与EWS或ETS部分相互作用的协同且可能受组织限制的转录因子可能会影响靶标选择。定义了两个融合伴侣的最小结构域,这些结构域已证明是鼠成纤维细胞体外转化所必需的。这些功能性研究提示了嵌合转录因子对转化靶基因的异常转录调控的作用。同样,两个不相关的蛋白质结构域的融合可能会影响整体蛋白质构象,从而影响DNA结合特异性。最近的证据表明,与转录因子融合的EWS与种系EWS相互作用的伙伴不同。 EWS-ETS基因融合体的变异性最近已被证明与临床结果相关。这一发现可能反映了各个嵌合转录因子的功能差异。备选地,在干细胞发育的不同时间点或在不同干细胞谱系中的特异性重组酶的类型和可用性可确定融合类型。使用EWS-ETS拮抗剂对EFT细胞系进行的研究确实表明,在EFT细胞的自我更新能力中,基因重排具有限速必不可少的作用。假定存在数量和类型不同的其他像差,这些像差可能会导致永生化和完全转换。有关此类继发性改变的知识可能会提供可用于治疗分层的有价值的预后指标。

著录项

  • 期刊名称 Sarcoma
  • 作者

    Heinrich Kovar;

  • 作者单位
  • 年(卷),期 1998(2),1
  • 年度 1998
  • 页码 3–17
  • 总页数 15
  • 原文格式 PDF
  • 正文语种
  • 中图分类 病毒传染病 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号